Malignant Pleural Mesothelioma Clinical Trials
6 recruiting trials for Malignant Pleural Mesothelioma. Eligibility criteria explained in plain English.
TrialFinderData lists 6 Malignant Pleural Mesothelioma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 33% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 2: 1, Phase 1: 1.
Research is led by University Hospital, Antwerp (1), University College, London (1), Cairo University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Dendritic cell vaccination (biological, 1 trial), followed by Atezolizumab, Platinum/pemetrexed based chemotherapy.
Track Malignant Pleural Mesothelioma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line...
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen...
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
Hemithoracic Arc Radiotherapy Post Pleural Decortication
Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with...
The IMmunotherapy Pleural 5-ALA PDT
Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with...
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Malignant Pleural Mesothelioma, with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Malignant Pleural Mesothelioma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Malignant Pleural Mesothelioma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.